NewsXbrane Biopharma releases interim report for the period April – June 2017

Xbrane  Biopharma  ABs  interim report for the period April – June 2017 is now available on the Company’s website,

April to June

  • Net sales SEK 4,514 thousand (1,032)
  • Total income SEK 4,700 thousand (1,108)
  • Earnings before tax SEK -9,388 thousand (-7,557)
  • Cash flow from current operations SEK -6,907 thousand (-8,842)
  • Earnings per share before dilution SEK -1.87 (-1.63)

Significant events during the second quarter

  • Xbrane reported positive comparative in-vivo effect data on Spherotide
  • Xbrane recruited Susanna Helgesen as new CFO / Head of Investor Relations
  • Xbrane raised SEK 20 million in a private placement with Carnegie Investment Bank AB as financial adviser
  • Xbrane launched a long term incentive program for its employees

Significant events after the second quarter

  • Spherotide was granted market authorization in Iran
  • The Board announces its intention to initiate the process of listing the Company’s shares at Nasdaq OMX’s Main list

For further information, please contact:

Martin Åmark
Chief Executive Officer
M: +46 (0) 763-093 777

Susanna Helgesen
CFO/IR, Xbrane Biopharma AB
M: +46 (0) 708-278 636

This information is information that Xbrane Biopharma AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation no. 596/2014. The information was submitted for publication, through the agency of the contact person set out above, at 08.00 August 31, 2017.

Xbrane Biopharma Q2-report ENG
PM Xbrane Biopharma release interim report for Q2